ZA201000354B - Dual modulators of 5-HT2A and D3 receptors - Google Patents

Dual modulators of 5-HT2A and D3 receptors

Info

Publication number
ZA201000354B
ZA201000354B ZA201000354A ZA201000354A ZA201000354B ZA 201000354 B ZA201000354 B ZA 201000354B ZA 201000354 A ZA201000354 A ZA 201000354A ZA 201000354 A ZA201000354 A ZA 201000354A ZA 201000354 B ZA201000354 B ZA 201000354B
Authority
ZA
South Africa
Prior art keywords
ht2a
receptors
dual modulators
modulators
dual
Prior art date
Application number
ZA201000354A
Other languages
English (en)
Inventor
Luca Gobbi
Georg Jaeschke
Olivier Roche
Sarmiento Rosa Maria Rodriguez
Lucinda Steward
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA201000354B publication Critical patent/ZA201000354B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA201000354A 2007-07-26 2010-01-18 Dual modulators of 5-HT2A and D3 receptors ZA201000354B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113252 2007-07-26

Publications (1)

Publication Number Publication Date
ZA201000354B true ZA201000354B (en) 2010-10-27

Family

ID=40281888

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201000354A ZA201000354B (en) 2007-07-26 2010-01-18 Dual modulators of 5-HT2A and D3 receptors

Country Status (16)

Country Link
US (4) US20090029977A1 (ru)
EP (1) EP2183245B1 (ru)
JP (1) JP5502733B2 (ru)
KR (1) KR101169518B1 (ru)
CN (1) CN101778844B (ru)
AR (1) AR067662A1 (ru)
AU (1) AU2008280187B2 (ru)
BR (1) BRPI0815092A2 (ru)
CA (1) CA2694009A1 (ru)
CL (1) CL2008002162A1 (ru)
ES (1) ES2498673T3 (ru)
PE (1) PE20090892A1 (ru)
RU (1) RU2480466C2 (ru)
TW (1) TWI363623B (ru)
WO (1) WO2009013212A2 (ru)
ZA (1) ZA201000354B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1987019B1 (en) * 2006-02-17 2012-11-28 F. Hoffmann-La Roche AG Benzoyl-piperidine derivatives as 5ht2/d3 modulators
CA2735400A1 (en) * 2008-09-22 2010-03-25 F. Hoffmann-La Roche Ag Piperazine d3 and 5-ht2a receptor modulators
JP2012502948A (ja) 2008-09-23 2012-02-02 エフ.ホフマン−ラ ロシュ アーゲー ドーパミンd3受容体の調節剤として有用なイソオキサゾロ[4,5]ピリジン−3−イル−ピペラジン誘導体
US8470828B2 (en) * 2010-07-06 2013-06-25 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8877778B2 (en) * 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8722683B2 (en) * 2011-02-17 2014-05-13 Hoffmann La-Roche Inc. Benzodioxole piperazine compounds
US8598357B2 (en) 2011-03-03 2013-12-03 Hoffmann-La Roche Inc. Benzodioxole piperidine compounds
US8921397B2 (en) * 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds
CN105367565B (zh) * 2014-08-20 2018-10-02 上海医药工业研究院 哌嗪(啶)环己基衍生物及其治疗精神神经疾病的应用
WO2017045599A1 (zh) * 2015-09-15 2017-03-23 浙江京新药业股份有限公司 环己烷衍生物或其立体异构体或盐及其制备与应用
CN106518841B (zh) * 2015-09-15 2019-03-05 浙江京新药业股份有限公司 环己烷衍生物或其立体异构体或盐及其制备与应用
JP7015092B2 (ja) 2016-07-28 2022-02-02 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する含窒素縮環化合物
KR20200112910A (ko) 2018-01-26 2020-10-05 시오노기 앤드 컴파니, 리미티드 도파민 d3 수용체 길항 작용을 갖는 축환 화합물
JP7250405B2 (ja) * 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する環式化合物
KR20220119597A (ko) 2019-10-29 2022-08-30 상하이 한서 바이오메디컬 컴퍼니 리미티드 4원 고리 유도체의 개질제, 및 이의 제조 방법 및 용도
WO2021088920A1 (zh) 2019-11-05 2021-05-14 上海翰森生物医药科技有限公司 苯并噻吩类衍生物调节剂、其制备方法和应用
KR20230004662A (ko) * 2020-04-26 2023-01-06 지앙수 엔화 파마수티컬 컴퍼니 리미티드 1,5-디하이드로-2,4-벤조디아제핀-3-온 유도체 및 이의 응용
CA3216904A1 (en) 2021-04-28 2022-11-03 Jinyao CHEN Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
DK60693D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
NZ336719A (en) 1997-02-07 2000-10-27 Hoechst Marion Roussel Inc 4-piperidinyl-1H-2-benzopyran derivatives useful as antipsychotic and process for preparation agents
ES2291023T3 (es) * 1998-02-09 2008-02-16 Duphar International Research B.V Derivados de benzisoxazol que tienen actividad antagonista de d4.
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
GB0117577D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
GB0117950D0 (en) 2001-02-16 2001-09-19 Aventis Pharma Inc Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands
MXPA03006524A (es) 2001-02-16 2003-09-25 Aventis Pharma Inc Derivados heterociclicos novedosos de amidas y su uso como ligandos para receptor d3 de dopamina.
EP1935887B1 (en) 2001-02-16 2010-01-13 Aventis Pharmaceuticals, Inc. Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
EP1987019B1 (en) * 2006-02-17 2012-11-28 F. Hoffmann-La Roche AG Benzoyl-piperidine derivatives as 5ht2/d3 modulators
WO2008052899A1 (en) * 2006-10-31 2008-05-08 F. Hoffmann-La Roche Ag Ether derivatives dual modulators of the 5-ht2a and d3 receptors
CN101778820B (zh) * 2007-08-09 2012-12-05 弗·哈夫曼-拉罗切有限公司 作为5-ht2a和d3受体双重调节剂的苯甲酰基-哌啶衍生物
CA2735400A1 (en) * 2008-09-22 2010-03-25 F. Hoffmann-La Roche Ag Piperazine d3 and 5-ht2a receptor modulators
PL2420558T3 (pl) * 2010-08-17 2017-12-29 The Procter And Gamble Company Stabilne, trwałe detergenty do ręcznego zmywania naczyń
US8877778B2 (en) * 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds

Also Published As

Publication number Publication date
JP2010534632A (ja) 2010-11-11
US8829029B2 (en) 2014-09-09
WO2009013212A2 (en) 2009-01-29
PE20090892A1 (es) 2009-07-13
AU2008280187A1 (en) 2009-01-29
RU2010104631A (ru) 2011-09-10
BRPI0815092A2 (pt) 2015-02-03
US20140350051A1 (en) 2014-11-27
CN101778844A (zh) 2010-07-14
EP2183245B1 (en) 2014-07-09
US20090029977A1 (en) 2009-01-29
AU2008280187B2 (en) 2013-05-16
AR067662A1 (es) 2009-10-21
KR20100036384A (ko) 2010-04-07
CN101778844B (zh) 2013-01-02
US20120040972A1 (en) 2012-02-16
KR101169518B1 (ko) 2012-07-27
TWI363623B (en) 2012-05-11
TW200911236A (en) 2009-03-16
EP2183245A2 (en) 2010-05-12
JP5502733B2 (ja) 2014-05-28
ES2498673T3 (es) 2014-09-25
US20130165432A1 (en) 2013-06-27
RU2480466C2 (ru) 2013-04-27
WO2009013212A3 (en) 2009-06-11
CA2694009A1 (en) 2009-01-29
CL2008002162A1 (es) 2009-05-29

Similar Documents

Publication Publication Date Title
ZA201000354B (en) Dual modulators of 5-HT2A and D3 receptors
IL210769A0 (en) Piperazine d3 and 5-ht2a receptor modulators
HK1211889A1 (en) Therapeutic use of diaminophenothiazines
EP2344484A4 (en) MODULATORS OF S1P RECEIVERS AND THEIR USE
IL198989A0 (en) Modulators of cb1 receptors
IL194556A0 (en) Diazepan derivatives modulators of chemokine receptors
GB0625196D0 (en) Modulators of cannabinoid receptor
PL2246339T3 (pl) Pochodne benzotiazepin i ich zastosowanie jako modulatorów receptorów AMPA i NMDA
PL2403505T3 (pl) Terapeutyczne zastosowania frakcji gumy mastyksowej
ZA201601457B (en) Modulators of 5-ht receptors and methods of use thereof
EP2166848A4 (en) SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS
EP2178371A4 (en) HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS
HK1160925A1 (zh) 組織蛋白酶 的用途
EP2249818A4 (en) HEDGEHOG SIGNAL AWAY ANTAGONISTS AND USE METHOD
ZA200807237B (en) Modulators of muscarinic receptors
GB0605900D0 (en) Modulators of nuclear receptors
IL218795A0 (en) Diazepam derivatives as modulators of chemokine receptors
ATE512137T1 (de) Benzoylpiperidinderivate als doppelmodulatoren des 5-ht2a- und des d3-rezeptors
EP2314588A4 (en) COMPOUNDS OF ESTROGENATED RECEPTOR MODULATORS AND THEIR USE
IL198157A0 (en) Ether derivatives dual modulators of the 5-ht2a and d3 receptors
ZA201101204B (en) Novel use application of sugar chain-recognizing receptor
HK1131039A1 (en) Pharmaceutical use of sophoricoside
GB0703514D0 (en) Use of riboflavin
EP2190286A4 (en) SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS
EP2421862A4 (en) OCTAHYDROBENZOISOCHINOLINE MODULATORS OF DOPAMINE RECEPTORS AND THEIR USE